Ofloxacin 200mg + Ornidazole 500mg
OFLOFT OZ combines ofloxacin and ornidazole in a single tablet, delivering dual bactericidal activity against aerobic gram-negative organisms and anaerobic/protozoal pathogens through mechanistically distinct pathways.
Ofloxacin (200mg) inhibits bacterial DNA gyrase and topoisomerase IV, causing lethal double-strand DNA breaks in aerobic gram-negative bacteria. Its near-98% oral bioavailability ensures systemic drug levels equivalent to intravenous administration, providing reliable coverage against E. coli, Klebsiella, Shigella, Salmonella, Campylobacter, and Pseudomonas — the most common aerobic gastrointestinal and ENT pathogens.
Ornidazole (500mg) is a second-generation nitroimidazole antiprotozoal and anaerobic antibiotic. It differs from metronidazole in having a longer half-life (12–14 hours versus 6–8 hours for metronidazole) and superior stability, enabling once or twice-daily dosing. Ornidazole is reduced by intracellular electron transport proteins in anaerobic organisms and protozoa, generating reactive nitro radicals that cause irreversible DNA strand breaks. It is active against Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis, and anaerobic bacteria including Bacteroides fragilis, Clostridium species, and Fusobacterium. Importantly, ornidazole does not cause the disulfiram-like reaction with alcohol that limits metronidazole compliance in many patients.
The combination provides complete coverage of the mixed aerobic-anaerobic polymicrobial infection spectrum — the clinical reality in most gastrointestinal, dental, and post-surgical infections.
OFLOFT OZ is indicated for polymicrobial infections involving aerobic gram-negative and anaerobic/protozoal pathogens — the most common microbial mix in gastrointestinal, dental, and intra-abdominal infections.
Gastrointestinal Infections (Primary Indication): Acute infectious diarrhoea, dysentery (bacillary and amoebic), Giardiasis, and gastroenteritis with mixed aerobic-anaerobic aetiology. A single product covers Shigella and amoeba simultaneously — critical in endemic tropical settings where co-infection is common.
Intra-Abdominal Infections: Post-operative peritonitis, cholecystitis, diverticulitis, and appendiceal infections as adjunct oral therapy following parenteral treatment.
Dental and Oral Infections: Periodontitis, periapical abscess, and post-extraction infections involving mixed aerobic-anaerobic oral flora — the ofloxacin covers gram-negative aerobes while ornidazole covers Bacteroides and Fusobacterium.
ENT Infections: Chronic suppurative otitis media with suspected mixed aerobic-anaerobic aetiology.
Pelvic Inflammatory Disease: Part of outpatient PID regimens covering Chlamydia (ofloxacin) and anaerobic co-pathogens (ornidazole).
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
Mixed aerobic-anaerobic gastrointestinal infections are the bread and butter of gastroenterology and general medicine outpatient practice. The clinical inconvenience and compliance challenge of prescribing two separate antibiotics — a fluoroquinolone for aerobes plus a nitroimidazole for anaerobes and protozoa — has driven strong market adoption of fixed-dose combinations like OFLOFT OZ.
Ornidazole's specific advantage over metronidazole — the absence of the disulfiram-alcohol interaction — is clinically meaningful in the Indian context where patient compliance with alcohol avoidance during metronidazole therapy is unreliable. Ornidazole eliminates this interaction risk entirely.
The special O2 dye with barcode print is a quality assurance feature that differentiates OFLOFT OZ from commodity alternatives, providing prescribers and pharmacists with an anti-counterfeiting verification mechanism — particularly important in a market where fixed-dose combination substandard products are a documented concern.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.